Sandbagging an Alzheimer’s Treatment – WSJ

The Meals and Drug Administration evaluates medicine for security and efficacy, however now the Facilities for Medicare and Medicaid Companies desires to behave as a political examine on the FDA’s choices. Final week CMS refused to cowl a novel Alzheimer’s therapy for hundreds of thousands of sufferers as a result of it disagreed with FDA approval.

Biogen ’s Aduhelm is the primary FDA-approved therapy proven to gradual the development of Alzheimer’s. However the drug is now ensnared in a political combat. The general public-health left thinks FDA is approving too many new costly medicine with marginal advantages, and it desires CMS to overrule the drug company. Progressives are cheering CMS’s Aduhelm determination as a precedent that the company can limit entry to new FDA-approved remedies. Aduhelm is the goal in the present day, however most cancers and gene therapies might be subsequent.

Source link

Leave a Reply

Your email address will not be published.